PeptiMed Inc

PeptiMed, Inc. operates as a bio-technology company. The Company develops a small interfering therapeutic drug that targets the EVI1 gene, called siEVI1, for treatment of advanced breast, prostate, lung, colon, ovarian, and skin cancers. PeptiMed serves patients in the United States.